

IFFIm Report

René Karsenti, Chair, IFFIm Board

GAVI Alliance Board Meeting Geneva, Switzerland 18 June 2014









IFFIm essentials

IFFIm makes GAVI more effective by:

- Increasing the available funding for life saving vaccines and immunisations
- Giving GAVI the flexibility to use funds when they are needed most
- Helping to drive down vaccine prices and increase security of vaccine supply by increasing the long-term predictability of funding
- Improving the efficiency of GAVI's financial management





IFFIm donor outreach

IFFIm Investment Case

- GAVI needs to raise an additional US\$ 7.5 billion for 2016-20 an average of US\$ 1.5 billion per year through direct contributions and proceeds of new pledges to IFFIm
- In consultation with donors since November 2013

Outreach to donors

- IFFIm Donors' meeting in Washington, DC (April 2014)
- Replenishment meeting in Brussels (May 2014)
- Social Impact Investment Taskforce of the International Development Working Group



IFFIm investor outreach

Investor outreach

- IFFIm is an important part of growing Socially Responsible Investment market niche for both retail and institutional investors
- Due diligence on Vaccine Bonds is easy because investment goes directly to vaccination programmes
- IFFIm Board outreach to the SRI community through individual meetings and conferences in London, Qatar, Brussels, New York, Paris, plus media outreach
- IFFIm remains competitive: weighted avg cost of 3-month USD Libor + 16 bps



GAVI Alliance Board meeting 18 June 2014



(US\$ million) Measles-rubella vaccine **┌** 0.2% 2.6% Meningitis eradication* Measles mortality reduction* 139.0 5.8% Polio eradication* 191.3 7.9% Maternal and neonatal tetanus* 2.5% Yellow fever stockpiles* 3.9% Other country-specific programmes 2.6% Health system strengthening (HSS) 280.8 11.6% 3.6 Measles vaccine 0.1% 38.1 Yellow fever vaccine 15.2 Rotavirus vaccine 0.6% Hepatitis B vaccine 0.5% Tetravalent vaccine (Diphtheria, tetanus, pertussis, hepB) 167 6.9% Pneumococcal vaccine Pentavalent vaccine 1,200 51.3% (Diphtheria, tetanus, pertussis, Hib, hepB) Total: US\$ 2.4 billion 2006 to March 2014 *One-time tactical investments in disease prevention and control ("investment cases") These tactical investments have helped prevent 1.4 million deaths from yellow fever, polio and measles. Such dedicated funding has also played a significant role in combating 600,000 cases of meningitis and maternal and neonatal tetanus.

Funding GAVI

Flexible funding

- IFFIm's long-term contributions provide a solid base for replenishment
- IFFIm provides flexible funding for GAVI that is outside of the replenishment cycle



Thank You

